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Granulocyte . Although the death rate associated with IHD has gradually declined over the last fifty years the incidence and prevalence of heart failure (HF) is on the increase and has become almost a pandemic. Paradoxically, the Center for Disease Control and Prevention have recently reported an increase in the ageadjusted rate for HF-related mortality. 2 The majority of treatment options in HF are palliative or aimed at slowing down disease progression (e.g. the prevention of cardiomyocyte loss or treatment of symptoms). In parallel to the increased incidence of HF, the use of new therapies such as coronary interventions, resynchronization therapy and the implantation of ventricular assist devices has also risen. As a consequence, hospitalisation due to HF has become more frequent, imposing a real economic burden on health care providers across the world. Therefore, there is an unmet clinical need to improve heart performance of patients who suffer IHD and HF and restore heart function.
Unlike many other tissues, heart muscle has a limited capacity to adequately repair itself after injury leading to progressive maladaptive remodelling and left ventricular dysfunction. Given the limited propensity for the heart to repair itself following injury, numerous strategies to repair or regenerate the damaged tissue have been proposed and tested in pre-clinical models and small to medium sized phase I and phase II clinical trials. 3, 4 One of the most promising strategies to repair or regenerate the damaged myocardium involves the use of cell-based therapies. The focus of this review is on the meta-analyses of RCTs for cell therapy in heart failure (HF) and acute myocardial infarction (AMI) using ostensibly autologous BMSC transplants.
Meta-analysis in preclinical models
Pre-clinical studies carried out in animal models present a unique opportunity to conduct homogenous trials, e.g. cell-treatment in a pre-specified time, similar animal strain and species, without confounding clinical factors. Recently, meta-analyses of a large number of pre-clinical studies of cell-based therapy in animal models of IHD have been published. [6] [7] [8] [9] Frequently, clinical outcomes (e.g. mortality) are not relevant in these studies, mostly due to the limited number of animals included in the studies and short follow-up times. However, efficacy parameters could be Although Zwetsloot et al., found that the large animal studies were superior in quality to their small animal counterparts, showed less evidence of publication and attrition biases, the differences in LVEF improvement between large and small animal preclinical models are not fully understood. 9 While these unresolved differences may have a methodological or biological origin, it is noteworthy that the smaller effects on LVEF improvement in large animal studies are more closely reminiscent of the trial data derived from human subjects and as such may indicate that large animal are the more appropriate preclinical model for stem cell therapy for cardiac repair. In order to standardize animal studies and to avoid or reduce heterogeneity, and to draw more meaningful conclusions, the NHLBI-sponsored CAESAR consortium and the Working Group on Cellular Biology of the Heart of the European Society of Cardiology have suggested, that pre-clinical studies should also be performed as multi-center randomized blinded studies, similar to human clinical trials.
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Meta-analyses of cell therapies in heart failure
Several small or medium-sized Phase I and II cell-based therapy studies have been 
Meta-analysis of cell therapy trials in acute myocardial infarction
As is the case with HF and IHD, several small or medium-sized phase I and II cell- Participants recruited to these trials presented LV dysfunction even after PCI and therefore, the rationale was that LVEF and LV volumes could be improved by cell transplantation. Therefore, changes in LVEF and LV volumes were the primary outcome of these trials. Cells were delivered mostly by infusion into the infarctrelated coronary artery (intracoronary cell delivery). Table 3 (Table 3 ). Subgroup analysis revealed that there was a statistically significant difference in LVEF in favour of BMSCs when cells were infused within 7 days following AMI and when the BMSC dose administered was higher than 10 8 cells. However, patients in the control group also showed a greater increase in LVEF if they were included into the trial within 7 days post-AMI. 25 In addition, the authors reported anecdotal trends in favour of benefit for most clinical outcomes examined, although none were statistically significant.
Meta-analysis of further trials incorporating increasing numbers of patients and
longer follow-ups have produced largely similar results (Table 3) RCTs have yet to consider the phenotypes of the transplanted cells, this is clearly one of the major sources of trial heterogeneity and may explain why certain patients may benefit from some cell therapy while others do not.
In addition to BMSCs, a meta-analysis of cell therapies from AMI using MSCs has recently been published. Wang and colleagues (Table 3) 
Individual patient data and trial sequential analysis
Prior to undertaking large scale clinical trials (Phase III), meta-analyses remain one the most widely used methods to evaluate the benefit of a given intervention.
However, findings derived from trial meta-analyses can be misleading if pitfalls in study designs, risk of reporting bias, and variation across studies are not carefully considered. 36, 37 To address some of the limitations and inherent biases associated with meta-analysis of RCTs, meta-analyses of individual patient data (IPD) and trial sequential analysis (TSA) have recently been applied to AMI trials. 25, 26, 38 . In addition to summary statistics derived from meta-analyses of multiple trials similar analyses can performed using IPD. 39 As its name suggests, IPD meta-analyses use prospective data derived from individual patients of all included studies removing the reliance on summary statistics for subsequent analyses. Thus, IPD-based metaanalyses contain transparent controlled data with unique definitions allowing data to be reanalysed en masse. Although IPD meta-analyses can help reduce bias associated with data analysis and reporting compared with trial meta-analyses, they cannot avoid bias or pitfalls associated with trial design. The first IPD-based meta-analysis of cell therapy trials for AMI, ACCRUE (meta-Analysis of Cell-based CaRdiac stUdiEs), collated data from 12 RCTs containing 1252 individuals (767 receiving cell therapy and 485 controls) ( Table 3) . 25 In agreement with the largest trials-based meta-analyses described above, the ACCRUE study found that intracoronary cell therapy for AMI had no apparent benefit on left ventricular function (including measurements of LV function made by MRI) and clinical outcomes in the treated group compared to the untreated controls.
Trial sequential analysis (TSA) has been used to resolve some of the inherent problems associated with trial meta-analysis such as insufficient statistical power 40, 41 . TSA leverages cumulative data to effectively reduce type I and type II errors and can be used to estimate information size (IS), similar to power calculations used in individual trials. Fisher and colleagues conducted a TSA on 41 AMI trials that included 2739 participants (Table 3) . 38 All trials administered BM-derived cells (mononuclear cell, BMMSCs, hematopoietic progenitors, circulating progenitor cells).
An 'a priori' threshold of relative risk reduction (RRR) in mortality of 35% was established as similar figure was empirically associated to percutaneous coronary intervention (PCI) in AMI 42 . In summary, cell therapies as currently tested in clinical trials do not seem to have a beneficial effect on clinical outcomes when administered to AMI patients.
Based upon TSA for AMI, the required IS to detect an effect of 35% RRR in mortality in favour of cell treatment was estimated to be 4,055 participants. Similarly, the required IS to detect a 35% RRR of re-hospitalization was 3,392 participants.
However, in practice many more patients will be required to detect smaller effect sizes. This study demonstrates that the current AMI RCTs and meta-analyses lack sufficient statistical power to detect clinically relevant outcomes explaining the inconsistent findings reported in different RCTs and their earlier meta-analyses that used shorter follow-up times.
Concluding remarks
Most meta-analyses reviewed herein seem to agree that the potential beneficial effect of cell therapies for HF and AMI is still inconclusive and statistically underpowered. In AMI, trial meta-analyses (including TSA) and IPD-based meta-analysis have drawn similar conclusions suggesting that cell-based therapies for AMI had no apparent clinical benefit. In addition, several recently published large RCTs,
that have yet to be included in meta-analyses, enrolling patients with ischemic HF and AMI, published neutral results regarding changes in LVEF between the cell treated and control groups. 5, [43] [44] [45] Furthermore, the recently published global position paper on cardiovascular regenerative medicine stated that, even if cell-based therapy in HF patients proved to be safe, the results are neither positive nor consistent. 46 In addition to the concerns regarding statistical power, the quality of the evidence in meta-analyses is confounded by two major sources of variation: (i) pitfalls in trial design and (ii) inconsistencies reporting and interpreting trial results. Therefore, there is a need for trial standardization and deep data sharing to improve reproducibility.
To this end, the ACCRUE consortium and guidelines published by the International Committee of Medical Journal Editors (ICMJE) recommend data sharing on publication of trial results (e.g. sharing of the de-identified IPDs in a confidential form within 6 months of the publication). 47, 48 These efforts will hopefully resolve the majority of the controversies in data interpretation and therefore will direct future clinical trials.
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